169 related articles for article (PubMed ID: 36325890)
1. An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence.
Holler M; Ihorst G; Reinhardt H; Rösner A; Braun M; Möller MD; Dreyling E; Schoeller K; Scheubeck S; Wäsch R; Engelhardt M
Haematologica; 2023 Apr; 108(4):1115-1126. PubMed ID: 36325890
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.
Djebbari F; Rampotas A; Panitsas F; Lim WY; Lees C; Tsagkaraki I; Gomes AR; Prideaux S; Chen L; Prodger C; Khera A; Gray N; Ellis L; Sangha G; Eyre TA; Moore S; Kothari J; Ramasamy K
PLoS One; 2022; 17(1):e0262388. PubMed ID: 35015781
[TBL] [Abstract][Full Text] [Related]
3. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.
Mateos MV; Dimopoulos MA; Cavo M; Suzuki K; Knop S; Doyen C; Lucio P; Nagy Z; Pour L; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Yoon SS; Iosava G; Fujisaki T; Garg M; Iida S; Bladé J; Ukropec J; Pei H; Van Rampelbergh R; Kudva A; Qi M; San-Miguel J
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):785-798. PubMed ID: 34344638
[TBL] [Abstract][Full Text] [Related]
4. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.
Facon T; Cook G; Usmani SZ; Hulin C; Kumar S; Plesner T; Touzeau C; Bahlis NJ; Basu S; Nahi H; Goldschmidt H; Quach H; Mohty M; Venner CP; Weisel K; Raje N; Hebraud B; Belhadj-Merzoug K; Benboubker L; Decaux O; Manier S; Caillot D; Ukropec J; Pei H; Van Rampelbergh R; Uhlar CM; Kobos R; Zweegman S
Leukemia; 2022 Apr; 36(4):1066-1077. PubMed ID: 34974527
[TBL] [Abstract][Full Text] [Related]
5. Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study.
Bringhen S; Pour L; Benjamin R; Grosicki S; Min CK; C de Farias DL; Vorog A; Labotka RJ; Wang B; Cherepanov D; Cain LE; Manne S; Rajkumar SV; Dimopoulos MA
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):491-504. PubMed ID: 37149398
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort.
Scheubeck S; Ihorst G; Schoeller K; Holler M; Möller MD; Reinhardt H; Wäsch R; Engelhardt M
Cancer; 2021 Sep; 127(18):3422-3436. PubMed ID: 34061991
[TBL] [Abstract][Full Text] [Related]
7. Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study.
Stege CAM; Nasserinejad K; van der Spek E; Bilgin YM; Kentos A; Sohne M; van Kampen RJW; Ludwig I; Thielen N; Durdu-Rayman N; de Graauw NCHP; van de Donk NWCJ; de Waal EGM; Vekemans MC; Timmers GJ; van der Klift M; Soechit S; Geerts PAF; Silbermann MH; Oosterveld M; Nijhof IS; Sonneveld P; Klein SK; Levin MD; Zweegman S
J Clin Oncol; 2021 Sep; 39(25):2758-2767. PubMed ID: 33945289
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
Bringhen S; D'Agostino M; Paris L; Ballanti S; Pescosta N; Spada S; Pezzatti S; Grasso M; Rota-Scalabrini D; De Rosa L; Pavone V; Gazzera G; Aquino S; Poggiu M; Santoro A; Gentile M; Baldini L; Petrucci MT; Tosi P; Marasca R; Cellini C; Palumbo A; Falco P; Hájek R; Boccadoro M; Larocca A
Haematologica; 2020 Jul; 105(7):1937-1947. PubMed ID: 31582542
[TBL] [Abstract][Full Text] [Related]
9. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma.
Facon T; Niesvizky R; Mateos MV; Siegel D; Rosenbaum C; Bringhen S; Weisel K; Ho PJ; Ludwig H; Kumar S; Wang K; Obreja M; Yang Z; Klippel Z; Mezzi K; Goldrick A; Tekle C; Dimopoulos MA
Blood Adv; 2020 Nov; 4(21):5449-5459. PubMed ID: 33166401
[TBL] [Abstract][Full Text] [Related]
11. Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients.
Djebbari F; Sharpley FA; McLain-Smith S; Vallance G; Eyre TA; Kothari J; Moore S; Ramasamy K
PLoS One; 2020; 15(2):e0229469. PubMed ID: 32084254
[TBL] [Abstract][Full Text] [Related]
12. Electronic FRAIL score may predict treatment outcomes in older adults with myeloma.
Chan H; Chong YH; Seow MY; Li J; Garg P; Kelly M; Neylon A; McDiarmid B; Tan S; Jackson S
J Geriatr Oncol; 2021 May; 12(4):515-520. PubMed ID: 33046409
[TBL] [Abstract][Full Text] [Related]
13. Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years.
Belotti A; Ribolla R; Cancelli V; Crippa C; Bianchetti N; Ferrari S; Bottelli C; Cattaneo C; Tucci A; De La Fuente Barrigon C; Rossi G
Am J Hematol; 2020 Jul; 95(7):759-765. PubMed ID: 32242970
[TBL] [Abstract][Full Text] [Related]
14. Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma.
Nakazato T; Hagihara M; Sahara N; Tamai Y; Ishii R; Tamaki S; Wake A; Tajika K; Sakai R; Kobayashi T; Hua J; Inoue M; Aisa Y; Fujisawa S; Miyazaki K; Irie S; Tanaka E; Higashihara M
Ann Hematol; 2021 Nov; 100(11):2745-2754. PubMed ID: 34333665
[TBL] [Abstract][Full Text] [Related]
15. Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Auner HW; Gavriatopoulou M; Delimpasi S; Simonova M; Spicka I; Pour L; Dimopoulos MA; Kriachok I; Pylypenko H; Leleu X; Doronin V; Usenko G; Hajek R; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Stevens DA; Quach H; Jagannath S; Moreau P; Levy M; Badros A; Anderson LD; Bahlis NJ; Facon T; Mateos MV; Cavo M; Chai Y; Arazy M; Shah J; Shacham S; Kauffman MG; Richardson PG; Grosicki S
Am J Hematol; 2021 Jun; 96(6):708-718. PubMed ID: 33755235
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and prognostic factors in patients with multiple myeloma in South Tyrol: a retrospective single-center analysis.
Mair M; Straka C; Buratti T; Tauber M; Mitterer M; Fong D
Ann Hematol; 2020 May; 99(5):1031-1040. PubMed ID: 32140891
[TBL] [Abstract][Full Text] [Related]
17. [Clinical features and prognosis of 93 elderly patients with multiple myeloma].
Chen HM; Zhou F; Wei W; Peng R; Shi HT; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):744-748. PubMed ID: 29081189
[No Abstract] [Full Text] [Related]
18. Development of a new clinical index to easily assess frailty of elderly patients with multiple myeloma in Asian population.
Lee HS; Lee J; Jo JC; Jung SH; Lee JJ; Kim D; Lee S; Song K
Sci Rep; 2021 Nov; 11(1):22907. PubMed ID: 34824362
[TBL] [Abstract][Full Text] [Related]
19. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
[TBL] [Abstract][Full Text] [Related]
20. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
